We report the case of a 48 year-old woman with primary Sjögren's syndrome (pSS) who developed a rare but important pulmonary disorder associated with this condition. This case highlights the difficulty in making the diagnosis of this rare pulmonary disorder and the treatment challenges it poses.
INTRODUCTION
Primary Sjögren's syndrome (pSS) is a chronic multisystem disorder characterised by lymphocytic infiltration of exocrine glands and extragrandular manifestations involving organs such as the skin, kidney, lungs as well as the vascular and neurological systems. Pulmonary involvement in patients with pSS include interstitial lung disease, airway disease, lymphoproliferative disease, pleural disease and rarely, pulmonary vascular disease.
CASE REPORT
A 35-year old woman presented in 1999 with severe symptoms of dry eyes and mouth, early morning stiffness and arthralgia. She was found to have antinuclear antibody (ANA) 1:360, rheumatoid factor (RF) 220 IU/ml (normal <15 IU/ml), a high erythrocyte sedimentation rate (ESR) of 50 mm/hr and positive anti-Ro and -La antibodies. Her complement levels, C3 and C4, were normal at presentation. She was initially treated with artificial tears and artificial saliva but required lacrimal duct occlusion because of severe keratoconjuctivitis of the right eye in 2009. There was no clinical or serological evidence for other connective tissue diseases and she was diagnosed with primary Sjögren's syndrome.
The patient was a non-smoker and had previously been treated for pulmonary tuberculosis (TB). She had recurrent sinusitis and chest infections, was diagnosed with bronchiectasis in 2000, and was seen regularly at a respiratory clinic. There was no evidence of malignancy on computed tomography (CT) of her paranasal sinuses and on nasopharyngeal biopsy. Epstein-Barr virus serology was negative.
In 2006, she developed an Ig G paraproteinaemia (Ig G 2420 mg/dl -upper limit normal 1725 mg/dl) and a trephine biopsy showed reactive megakaryocytic hyperplasia with mild interstitial prominence of plasma cells. Her treatment included thalidomide, bortezomib and rituximab, which reduced her Ig G level to 1770 mg/dl in 2011. She was given longterm prophylaxis with isoniazid and septrin.
In 2009, a CXR showed enlargement of a cavitating lesion in the right apex of the lung, first detected The HRCT showed multiple cystic lesions with scarring in the right lung apex and traction bronchiectasis. There was left apical scarring from previous tuberculosis. Multiple subpleural nodules/ focal pleural thickening were noted in the upper lobes and multiple ill-defined centrilobular nodules were seen in the basal segment of the right lower lobe. Bronchiectatic changes were noted in the basal segments of both lower lobes. These findings were reported as consistent with lymphocytic interstitial pneumonia. Sputum culture did not reveal active infection in the lungs. In particular, sputum culture for acid fast bacillus (AFB) was negative.
Concurrently, the right parotid gland was biopsied and showed extra-nodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). She was treated with fludarabine and radiotherapy with complete resolution of the MALT lymphoma.
By 2012, the right lower zone (RLZ) bulla had expanded across the midline with attenuation of the mediastinum (Fig. 1 ). Video-assisted thorascopic surgery with RLZ bullectomy was performed. Histopathological examination of the substantial lung wedge excision confirmed the presence of bulla-like cystic change in the subpleural regions with the presence of a prominent chronic bronchiolitis and a more minor and patchy element with a non-specific interstitial pneumonitis (NSIP) pattern, grade 1. There was only mild fibrosis and no significant smooth muscle metaplasia. A small focus of amyloid (around 2 to 3 mm), which stained salmon pink with congo red, and showed apple-green birefringence under polarised light was confined to one area around two small-calibre vessels. The amyloid deposit with multinucleated giant cells surrounding each aggregate is depicted in Fig.  2 . These histological features are in keeping with localised pulmonary nodular amyloidosis. Further blocks were taken and examined for evaluation of the entire wedge of lung resected and confirmed the absence of MALT lymphoma in the lung or other foci of amyloid deposition. There was also no light chain restriction by immunohistochemistry.
DISCUSSION
Sjögren's syndrome (SS) is an autoimmune inflammatory disorder with lymphocytic infiltration of exocrine glands and autoantibody production. Primary Sjögren's syndrome has an estimated prevalence of 0.1-0.6% in the general adult population. Secondary Sjögren's syndrome (sSS) is associated with other autoimmune systemic diseases such as rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis.
Lymphocytic infiltration of the salivary and lacrimal glands causes sicca symptoms of eyes and mouth but extraglandular systemic involvement can cause significant pathology in major organs such as kidneys, liver and lungs. Immune complex deposition which arises from persistent B cell proliferation is associated with peripheral neuropathy and increased risk of lymphoma, especially in those with hypergammaglobulinaemia, anti-Ro and -La antibodies, cryoglobulinaemia and low complement levels 1 , as well as small vessel skin vasculitis, reduced CD4 cells and CD4/CD8 ratio, respectively 2 .
Pulmonary involvement in pSS is increasingly recognised and can present with airway, parenchymal, pleural or vascular manifestations 3 . The reported prevalence of pulmonary involvement in SS varies, according to which criteria are used in the diagnosis of pulmonary disease, whether the data include patients with both pSS and sSS, and what diagnostic criteria are used e.g. bronchoalveolar lavage, chest CT. When only clinically significant pulmonary involvement is considered, a prevalence Proceedings of Singapore Healthcare  Volume 23  Number 4  2014 of 9-12% has consistently been reported from Europe, Japan, Turkey and USA 4,5 .
Our patient had multiple cysts and nodules on HRCT, and the histology of the wedge excision of her lung confirmed the presence of bulla-like cystic change in the subpleural regions with the presence of a prominent chronic bronchiolitis and a more minor and patchy element with a non-specific interstitial pneumonitis (NSIP pattern, grade 1) with only mild fibrosis and no significant smooth muscle metaplasia. The small focus of amyloid, approximately 2 to 3 mm, was confined to one area, reflective of localised nodular amyloidosis.
These changes are echoed in a study by Baqir et al. 6 where they found that all (eight) patients with pSS and a diagnosis of pulmonary amyloidosis on lung biopsy had cysts and nodules on CT chest and histological examination of lung tissue yielded light chain (AL) amyloid. Light chain amyloid in SS has most frequently been reported as localised nodular pulmonary amyloidosis. We were not able to characterise further the type of amyloid in our patient as the focus of amyloid was too small on deeper sectioning. Nonetheless, the histopathological appearances are entirely consistent with those of cystic lung disease associated with Sjögren's syndrome comprising a chronic bronchiolitis, with a minor element of NSIP and localised nodular amyloid deposition as described by Tansey et al 7 .
In their study, Tansey et al. reviewed 54 lung biopsies from 37 patients with different connective tissue disorders (CTDs) including polymyositis/ dermatomyositis, Sjögren's syndrome, rheumatoid arthritis and systemic lupus erythematosus. They assessed the overall and relative frequencies of patterns of interstitial pneumonia and their impact on prognosis. Non-specific interstitial pneumonitis was the most common pattern with an overall biopsy prevalence of 39% and patient prevalence of 41%. However, there was variation in prevalence between different CTDs. In particular, SS commonly showed chronic bronchiolitis, and was the only CTD in which amyloidosis was noted, supporting published data in which amyloidosis appears more commonly associated with SS than with other CTDs 4,8,9 . There are few reports of multiple bullae and pulmonary nodular amyloidosis in pSS. The first Proceedings of Singapore Healthcare  Volume 23  Number 4  2014 case was described by Kobayashi and colleagues in 1988 9 . The authors noted the infiltration of lymphocytes and plasma cells into the bronchiolar wall, without involvement of other lung regions. They postulated that the mechanism of bullae formation might involve inflammatory cell infiltration into the bronchial wall, causing narrowing of the airways, so that cell infiltration acts as a check valve mechanism. Jeong et al. 10 described pathological findings in a SS patient with cystic lung disease and pulmonary amyloidosis in whom the cyst seemed to be located distal to bronchioles narrowed by amyloid deposition and lymphocytic cell infiltration. On the other hand, Colombat et al. 11 showed that metalloproteinases released by macrophages caused elastolysis and cystic lung disease in pulmonary light chain deposition disease. It is possible that multiple mechanisms lead to development of cystic lung lesions in patients with SS-associated pulmonary amyloidosis. Further evaluation with larger lung specimens may yield clarification on how cysts form.
As pulmonary nodular amyloidosis and cystic lung disease associated with pSS is uncommon, no randomised controlled trials exist to guide treatment. Corticosteroids are commonly used for the treatment of interstitial lung disease associated with pSS, alone or in combination with other immunosuppressives such as azathioprine 12 . Several treatments directed against B cells, e.g. the anti-CD 20 agent, rituximab, require larger randomised trials to assess the long-term effects of such treatments in pSS.
CONCLUSION
The prognosis of patients with pSS with or without lung involvement is good. A first analysis of causespecific standardised mortality ratios (SMR) in a prospective cohort with pSS 13 has not shown an increase in all-cause mortality in pSS compared with the general population. Excess mortality in this cohort was due to lymphoproliferative malignancy and the strongest predictor for unfavourable outcome was low C3 and/or C4 at the time of diagnosis. On the whole, pSS patients with ILD are asymptomatic at the time of initial radiological studies 14, 15 . Patients with predictors of poorer prognosis warrant close observation and earlier investigations.
